Midatech Pharma PLC - MTX110 Study to be Presented at ISPNO 2022
Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP) has announced the presentation of interim results from a Phase 1 study on its drug MTX110 for treating Diffuse Intrinsic Pontine Glioma (DIPG). The presentation will occur on June 13, 2022, at the International Symposium on Pediatric Neuro-Oncology in Hamburg, Germany. Initial data will cover safety findings from seven patients using a continuous drug delivery system. MTX110 aims to enhance treatment efficacy against DIPG by allowing higher drug concentrations while reducing systemic toxicity.
- Presentation of interim results for MTX110 signals ongoing clinical development.
- First safety data from the study shows promise in treating DIPG patients.
- Innovative catheter system enhances drug delivery directly to the tumor site.
- None.
ABINGDON, OXFORDSHIRE / ACCESSWIRE / June 10, 2022 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that investigators from Columbia University Irving Medical Center and New York-Presbyterian will present interim results from their ongoing Phase 1 study on Midatech's MTX110 in Diffuse Intrinsic Pontine Glioma ("DIPG") at The International Symposium on Pediatric Neuro-Oncology ("ISPNO 2022") that will take place on 12-15 June 2022 in Hamburg, Germany. The presentation is titled: "A Phase I study examining the feasibility of intermittent convection-enhanced delivery (CED) of MTX110 for the treatment of children with newly diagnosed diffuse midline gliomas."
The presentation will take place on 13 June 2022 in the neurosurgery section of the conference, at 10.30 am CEST. The investigators will show first data on seven out of the ten planned patients on the safety of MTX110 (a water-soluble formulation of panobinostat) in patients with DIPG. This study uses an implantable pump and catheter system that allows for continuous intratumoral administration of the study drug without the need for repeated surgery. The study continues its recruitment.
The agenda of the meeting may be found here:
https://www.ispno2022.de/program/scientific-program/
Commenting, Dmitry Zamoryakhin, CSO of Midatech, said: "The presentation by the investigators from Columbia University Irving Medical Center and New York-Presbyterian will show first data on the safety of MTX110 use in patients with DIPG. This study uses an implantable pump and catheter system that allows for continuous intratumoral administration of the study drug without the need for repeated surgery. The same device is going to be used in another study of MTX110 in adult patients with recurrent glioblastoma, which we aim to begin in the second half of 2022."
About MTX110
MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour. Panobinostat is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). The currently available oral formulation of panobinostat lactate (Farydak®) is not suitable for treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations. Based on favourable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG (NCT03566199, NCT04264143) and recurrent medulloblastoma (NCT04315064), and preclinically for treatment of glioblastoma (SNO 2020 Abstract TMOD-27). MTX110 is delivered directly into and around the patient's tumour via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood-brain barrier. This technique exposes the tumour to very high drug concentrations while simultaneously minimising systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in in vitro and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patient-derived DIPG cell lines (Grasso et al, 2015. Nature Medicine 21(6), 555-559).
For more information, please contact:
|
Dmitry Zamoryakhin, CSO |
Tel: +44 (0)29 20480 180 |
Strand Hanson Limited (Nominated and Financial Adviser) |
James Dance / Matthew Chandler / Rob Patrick |
Tel: +44 (0)20 7409 3494 |
Turner Pope Investments (TPI) Limited (Joint Broker) |
Andrew Thacker (Corporate Broking) Tel: +44 (0)20 3657 0050 |
IFC Advisory Limited (Financial PR and UK Investor Relations) |
Tim Metcalfe / Graham Herring |
Tel: +44 (0)20 3934 6630 |
Edison Group (US Investor Relations) |
| Alyssa Factor |
| Tel: +1 (860) 573 9637 |
| Email: afactor@edisongroup.com |
About Midatech Pharma PLC
Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:
- Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).
- MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.
- MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease.
The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States Private Securities Litigation Reform Act. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.
Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Midatech Pharma PLC
View source version on accesswire.com:
https://www.accesswire.com/704613/Midatech-Pharma-PLC--MTX110-Study-to-be-Presented-at-ISPNO-2022
FAQ
What are the interim results of MTX110 for DIPG presented by Midatech Pharma?
When will the MTX110 study results be presented?
What is the significance of MTX110 in treating DIPG?
Who is conducting the MTX110 study for DIPG?
What is the delivery method for MTX110 in the study?
